Datamonitor - aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapidly evolving marketplace

The Datamonitor Group aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapi...

Laboratory

Labs are the hub of much of modern medicine, either in the hospital setting processing patients blood tests and other samples, in research institutions at many universities or in the headquarters of...

OxyContin

OxyContin, an narcotic analgesic produced by Purdue Pharma LP, nets $3m in sales annually, placing it 8th in the world for annual sales. OxyContin in the brand name for oxycodone, and is similar t...

Lyxumia

Lyxumia® is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of patients with type 2 diabetes mellitus. GLP-1 is a naturally-occurring peptide hormone that is re...

Devices - medical, biotech, pharma

A medical device is a product which is used for medical purposes in patients, in diagnosis, therapy or surgery.  Medical devices act by physical, mechanical, thermal, physico-chemical or chemic...

Hong Kong’s CK Life To Spin Off U.S. R&D Unit Polynoma, Keep Control

Hong Kong’s CK Life Sciences International intends to establish its U.S.-based subsidiary, Polynoma, as a separate company for research and development, including work on a vaccine for melanoma set...

Polynoma initiates POL 103A Phase III trial in melanoma

Polynoma LLC, a U.S. oncology-focused biopharmaceutical company within Hong Kong-based CK Life Sciences Int'l., today announced the start of a Phase III clinical trial program for POL 103A, the Compan...

Polynoma Appoints John Chiplin, Ph.D., Chief Executive Officer

Polynoma, Inc., an oncology-focused biotechnology company within Hong Kong-based CK Life Sciences Int’l., (Holdings) Inc., today announced the appointment of John Chiplin, Ph.D....

Polynoma Announces Appointment of New Members to Senior Management Team

Polynoma LLC, a U.S. oncology-focused biotechnology company within Hong Kong-based CK Life Sciences Int’l., (Holdings) Inc., today announced the expansion of the Company’s sen...

Polynoma Commences Phase III Melanoma Vaccine Clinical Trial

Polynoma LLC, a U.S. oncology-focused biopharmaceutical company within Hong Kong-based CK Life Sciences Int’l., (Holdings) Inc., today announced the start of a Phase III clinic...

Pharma 3.0 Pulls Companies into the Digital Future

Social media and mobile marketing have kick-started the pharma industry into a phase dubbed Pharma 3.0.  Gone are the days of Pharma 1.0 in which companies could rely on a handful of blockbuster drug...

Big pharma companies BMS and Merck are pharma partnering on Daclatasvir

Big pharma company, Bristol-Myers Squibb, is pharma partnering with another big pharma company, Merck, to develop Daclatasvir to treat Hepatitis C. The big pharma companies will work on the hepatitis...

Merck enter pharma partnering pact with Ra Pharma for cyclomimetics

Ra Pharmaceuticals has entered into a pharma partnering deal with Merck, a top 50 big pharma corporation, focused on the development of Cyclomimetics, a new class of compounds that have the diversity...

Comment about the article "Psychopharmaceuticals and diabetes" of Ress C, Tschoner A, Kaser S, and Ebenbichler CF in Wiener Medizinische Wochenschrift 2011; 161/21-22: 531-42.

Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.

Structures containing the (R)-3-amino-3-methyl piperidine unit as a new pharmacophore moiety have been shown to possess moderate inhibitory activity for DPP-4 with good pharmacokinetics profile. One o...

Is pharma running out of brainy ideas?

Big pharma moves from 'blockbusters' to 'niche busters'.

China spurs pharma innovation.